Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross Arthropathy Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentPremera BluecrossPolicy 5.01.550

    Pharmacotherapy of Arthropathies

    Customize your policy alerts

    Sign up for Premera Bluecross Policy 5.01.550 alerts

    Get alerted when Policy 5.01.550 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity, prior authorization, step therapy, and site-of-service review for intravenous and injectable therapies used to treat inflammatory arthropathies.

    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacotherapy of Arthropathies
    Policy CodePolicy 5.01.550
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionDocument the diagnosis, age, prior treatment response or intolerance, and rheumatologist prescribing or consultation for authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    13+Site-of-service review age
    90 daysHospital outpatient initial or re-initiation period
    50 milesInfusion-center access threshold
    2Prior advanced agents commonly required

    Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Ankylosing spondylitis

    Covered when applicable drug-specific criteria are met.

    Ankylosing spondylitis criteria

    • Prior-treatment pathway: For applicable second-line products, the individual has inadequate response or intolerance to the specified number and list of prior agents.One or two prior agents, depending on the drug

    Polyarticular juvenile idiopathic arthritis

    Covered when all applicable criteria are met.

    Core criteria

    • Escalation pathway: For specified second-line therapies, the individual has inadequate response or intolerance to two listed drugs or has a qualifying condition such as heart failure or a previously treated lymphoproliferative disorder.Two prior drugs for the standard pathway

    Second-line therapy for polyarticular juvenile idiopathic arthritis

    Covered when all stated criteria are met.

    Kevzara or Orencia criteria

    • Qualifying pathway: Inadequate response or intolerance to two listed agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder, as applicable.Two prior agents or one qualifying condition

    Site-of-service medical necessity

    Site-of-service administration is medically necessary when one of the following applies.

    Medically necessary site of service: Administration occurs in a physician's office, infusion center, hospital-based outpatient setting, or outpatient hospital IV infusion department as an appropriate, safe, and cost-effective site.
    Hospital outpatient exceptions: Hospital-based outpatient administration is used during the first 90 days of initial or reinitiated therapy, when no outpatient infusion center is within 50 miles and no contracted home-infusion agency will travel to the home, when the hospital is the only site offering the drug, or when a qualifying clinical condition increases infusion or injection risk.First 90 days; 50-mile access threshold

    Polyarticular juvenile idiopathic arthritis

    Covered when all applicable criteria are met.

    Polyarticular JIA eligibility

    • Prior targeted therapy or clinical pathway: Inadequate response or intolerance to two listed targeted agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder, where applicable.Two agents or one qualifying condition

    Orencia for polyarticular juvenile idiopathic arthritis

    Covered when all criteria are met.

    Orencia polyarticular JIA criteria

    • Qualifying pathway: Inadequate response or intolerance to two listed agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two prior agents or one qualifying condition

    Polyarticular JIA second-line TNF-alpha antagonists

    Covered when all criteria are met.

    Second-line TNF-alpha antagonist criteria

    • Product-specific prior treatment: For Humira, Hyrimoz, and Simlandi, inadequate response or intolerance to all specified first-line adalimumab products; for Cimzia, inadequate response or intolerance to two listed agents.All specified adalimumab products or two agents

    Systemic juvenile idiopathic arthritis

    Covered when all stated criteria are met.

    Systemic JIA criteria: The individual is at least 2 years old, has inadequate response or intolerance to the required prior therapy, and the medication is prescribed by or in consultation with a rheumatologist.Age 2 years or older

    The specific prior therapy is not fully visible in the source excerpt.

    Enthesitis-related arthritis

    Covered when all criteria are met.

    Enthesitis-related arthritis criteria: The individual is at least 4 years old and Cosentyx is prescribed by or in consultation with a rheumatologist.Age 4 years or older

    Rheumatoid arthritis first-line biologic and targeted agents

    Covered when all applicable criteria are met.

    Rheumatoid arthritis first-line criteria: The individual is at least 18 years old, has moderate-to-severe rheumatoid arthritis, has inadequate response or intolerance to the applicable conventional therapies, and the medication is prescribed by or in consultation with a rheumatologist.Age 18 years or older

    Conventional therapies include hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; requirements vary by agent.

    Rheumatoid arthritis Janus kinase inhibitors

    Covered when all criteria are met.

    JAK inhibitor criteria: The individual is at least 18 years old, has moderate-to-severe rheumatoid arthritis, has inadequate response or intolerance to one or more TNF blockers, and the medication is prescribed by or in consultation with a rheumatologist.Age 18 years or older; at least one TNF blocker failed or not tolerated

    JAK inhibitor therapy

    Covered when all criteria are met.

    JAK inhibitor therapy: Treatment is for moderate-to-severe rheumatoid arthritis; the individual is at least 18 years old; the individual has inadequate response or intolerance to one or more TNF blockers; and the medication is prescribed by or in consultation with a rheumatologist.Age 18 years or older; at least one TNF blocker failed or not tolerated

    Adalimumab biosimilar therapy

    Covered when all stated criteria are met.

    Adalimumab biosimilar criteria: Treatment is for moderate-to-severe rheumatoid arthritis; the individual is at least 18 years old; the individual has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; the medication is prescribed by or in consultation with a rheumatologist; and the additional agents specified for the requested product have also been tried and not tolerated or effective.Age 18 years or older

    Cimzia, Immgolis, and Simponi

    Covered when all stated criteria are met.

    TNF antagonist criteria: Treatment is for moderate-to-severe rheumatoid arthritis; the individual is at least 18 years old; the individual has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; the individual has inadequate response or intolerance to two specified advanced agents; and the medication is prescribed by or in consultation with a rheumatologist.Age 18 years or older; two advanced agents

    Infliximab therapy

    Covered when all criteria are met.

    Infliximab criteria: Treatment is for moderate-to-severe rheumatoid arthritis; the individual is at least 18 years old; the individual has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; the individual has inadequate response or intolerance to Avsola, Inflectra, and Renflexis when not previously treated with the requested therapy; and the medication is prescribed by or in consultation with a rheumatologist.Age 18 years or older

    Kevzara

    Covered when all base criteria and one alternative pathway are met.

    Kevzara base criteria

    • Alternative pathway: Inadequate response or intolerance to two specified agents, or heart failure or a previously treated lymphoproliferative disorder.Two agents or one qualifying condition

    Kineret

    Covered when all criteria are met.

    Kineret criteria: Treatment is for moderate-to-severe rheumatoid arthritis; the individual is at least 18 years old; the individual has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; and the individual has inadequate response or intolerance to two specified advanced agents.Age 18 years or older; two advanced agents

    Orencia

    Covered when all base criteria and one alternative pathway are met.

    Orencia criteria

    • Advanced-therapy pathway: Inadequate response or intolerance to two specified agents, or the applicable heart-failure or previously treated lymphoproliferative-disorder pathway.Two agents or one qualifying condition

    TNF-alpha Antagonists - First Line

    Coverage requires all of the following, plus one qualifying pathway.

    Baseline requirements: The individual is at least 18 years old and has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.Age 18 years or older
    Advanced-agent failure or clinical exception: Inadequate response or intolerance to two specified agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    TNF-alpha antagonist first-line criteria

    Coverage requires the stated conventional-therapy history and one advanced-therapy pathway.

    Conventional therapy: The patient has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    Advanced-therapy pathway: The patient has inadequate response or intolerance to two listed advanced agents, or has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    TNF-alpha antagonist first-line authorization criteria

    Coverage requires the conventional-therapy prerequisite and one additional pathway.

    Conventional therapy history: The individual has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    Additional pathway: The individual has inadequate response or intolerance to two listed targeted agents, or has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two targeted agents or one qualifying condition

    First-line TNF-alpha antagonist and targeted therapy criteria

    Coverage requires the applicable clinical pathway.

    Conventional therapy: The member has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    Advanced therapy or qualifying condition: The member has inadequate response or intolerance to two listed agents, or has heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    TNF-alpha antagonist first-line coverage criteria

    Covered when all applicable requirements are met.

    Core requirements

    • Targeted-agent failure or clinical exception: Inadequate response or intolerance to two listed targeted agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    First-line TNFα antagonist and related-agent criteria

    Coverage requires all applicable conditions.

    Required clinical pathway

    • Advanced-agent failure or clinical exception: Inadequate response or intolerance to two listed agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Targeted therapy authorization criteria

    Covered when the applicable criteria are met.

    Baseline therapy

    • Targeted-agent or clinical-exception pathway: Inadequate response or intolerance to two listed targeted agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    TNF-alpha antagonists - first-line therapy

    Covered when all of the following are met.

    TNF-alpha antagonist criteria

    • Qualifying pathway: Inadequate response or intolerance to at least two specified agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.At least two agents or one qualifying condition

    Initial specialty-drug therapy criteria

    Coverage requires the conventional-therapy prerequisite and one qualifying pathway.

    Baseline requirements

    • Qualifying pathway: Inadequate response or intolerance to two listed specialty agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two specialty agents or one qualifying condition

    First-line advanced therapy criteria

    Covered when all base requirements and one advanced-therapy pathway are met.

    Base requirements

    • Advanced-therapy pathway: Inadequate response or intolerance to two listed advanced agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    First-line TNF-alpha antagonist therapy

    Coverage requires all of the following, with one alternative pathway.

    Required criteria

    • Additional pathway: Inadequate response or intolerance to two listed agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    TNFα antagonist first-line therapy

    Coverage requires the applicable prior-treatment and specialist requirements.

    Core requirements

    • Qualifying pathway: Inadequate response or intolerance to two listed agents or agent groups, or a qualifying history of heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Alaska fully insured members are exempt from site-of-service medical-necessity criteria. These members are reviewed under the applicable infusion and injection drug medical-necessity criteria only.

    The criteria in this policy do not apply to members enrolled in the custom Open formulary identified as Formulary ID 6062 / Rx Plan F1. Evaluate those requests under Policy 5.01.647, Medical Necessity Criteria for Custom Open Formulary, after verifying the member’s plan booklet or identification card.

    Intravenous drugs described in this policy must be processed under the medical benefit, not the pharmacy benefit.

    Tofacitinib use for alopecia is considered cosmetic and is not covered under this policy.

    Tofacitinib use for alopecia is considered cosmetic and is not covered under this policy.

    Hospital-based outpatient administration of infusion and injectable therapy is not medically necessary when the policy’s site-of-service criteria are not met. Such administration may be supported under specified circumstances, including the first 90 days of initial or reinitiated therapy, qualifying clinical risk, or documented access limitations.

    Coding and Operational Parameters

    Referenced NDC prefixesNDC
    NDCs starting with 00597Adalimumab-adbm product identifiers referenced in the policy
    NDCs starting with 82009Adalimumab-adbm product identifiers referenced in the polyarticular juvenile idiopathic arthritis second-line tier
    NDC Prefixes ReferencedNDC
    00597NDCs starting with 00597 for adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm
    82009NDCs starting with 82009 for adalimumab-adbm
    NDC Identifier Referenced in CriteriaNDC
    00597NDCs starting with 00597 for specified adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm products
    NDC product identifierNDC
    NDCs starting with 00597Adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm products with NDCs starting with 00597
    Specified adalimumab NDC prefixNDC
    NDCs starting with 00597NDCs starting with 00597 for specified adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm products
    Specified NDC labeler prefixNDC
    NDCs starting with 00597Adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm products identified by NDCs starting with 00597
    Referenced NDC identifierNDC
    NDCs starting with 00597Adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm products
    NDC identifier referenced for adalimumab productsNDC
    00597Adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm NDCs starting with 00597
    Referenced drug identifierNDC
    NDCs starting with 00597Adalimumab-aaty, adalimumab-adaz, or adalimumab-adbm products
    Site-of-service review age
    Review applies atAged 13 years and older
    Review typeSite-of-service medical necessity review
    Benefit scopeMedical benefit reviews only
    Hospital-based outpatient initial or re-initiation period
    Covered periodFirst 90 days
    Initial therapyInitial course of infusion or injection
    Re-initiation therapyRestarting an agent after 6 months or longer following discontinuation
    Infusion-center distance exception
    Distance exceptionNo outpatient infusion center within 50 miles of the individual's home
    Home-infusion conditionNo contracted home infusion agency will travel to the individual's home
    Alternative access conditionThe hospital is the only place that offers infusions or injections of the drug
    Kevzara weight requirement
    Minimum weightAt least 63 kg
    DrugKevzara (sarilumab) SC
    IndicationPolyarticular juvenile idiopathic arthritis
    Adult ankylosing spondylitis age requirement
    Minimum age18 years or older
    ConditionAnkylosing spondylitis
    Prescriber requirementPrescribed by or in consultation with a rheumatologist
    Polyarticular juvenile idiopathic arthritis age requirement
    Minimum age2 years or older
    ConditionPolyarticular juvenile idiopathic arthritis
    Additional criterionAggressive disease when required by the requested therapy
    Number of targeted agents failed or not tolerated
    Standard requirementAt least 2 agents
    Failure standardInadequate response or intolerance
    Agent typeSpecified targeted agents
    Prior agent response or intolerance
    Required historyInadequate response or intolerance to 2 listed agents
    Alternative pathwayA qualifying clinical history may apply instead
    Specialist requirementPrescribed by or in consultation with a rheumatologist

    Provider Actions and Authorization Requirements

    Billing Rule

    Medical and Site-of-Service Review

    Review covered IV and injectable drugs for medical necessity for all ages. For members age 13 and older, also review the administration site; site of service includes hospital outpatient, infusion center, physician office, and home.

    • SOS criteria apply only to medical-benefit reviews.
    • IV claims must process through the medical benefit, not pharmacy.
    Prior Authorization

    Disease-Specific Authorization

    Obtain disease-specific authorization before administering or dispensing the requested agent. Apply the criteria for the member’s diagnosis, age, route, product, and benefit.

    • Covered disease pathways include ankylosing spondylitis, polyarticular and systemic JIA, enthesitis-related arthritis, and rheumatoid arthritis.
    Note

    Alaska Fully Insured Exception

    Do not apply site-of-service medical-necessity criteria to Alaska fully insured members. For these members, apply only the infusion and injection drug medical-necessity criteria and contact Customer Service for questions.

    • The Alaska exception does not remove applicable drug authorization requirements.
    Prior Authorization

    Medical-Necessity Review

    Document the diagnosis, disease severity, age, requested product and route, prior treatment response or intolerance, and prescriber qualifications to support medical necessity.

    • Criteria vary by disease and product.
    • A failure to establish medical necessity may result in denial.
    Prior Authorization

    Adult Rheumatoid Arthritis Authorization

    For adult moderate-to-severe rheumatoid arthritis, verify age 18 or older, inadequate response or intolerance to conventional therapies, required prior advanced-agent failures, and rheumatologist prescribing or consultation.

    • Conventional therapies include hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine.
    • Document qualifying exceptions such as heart failure or previously treated lymphoproliferative disorder when applicable.
    Step Therapy

    Infliximab Product Sequencing

    For infliximab (Janssen-unbranded) and Remicade, document inadequate response or intolerance to Avsola, Inflectra, and Renflexis when the member has not previously received the requested therapy.

    • The referenced infliximab products are also subject to site-of-service review when administered IV.
    Step Therapy

    Second-Line Advanced Therapy Prerequisites

    Second-line advanced therapies generally require inadequate response or intolerance to conventional DMARD therapy plus the specified number of first-line or other advanced agents, unless a listed clinical exception applies.

    • Examples include failure of two listed agents or qualifying heart failure, lymphoproliferative disorder, serious infection, or demyelinating disorder.
    • Prescribing by or consultation with a rheumatologist is generally required.
    Prior Authorization

    Adult Patient and Treatment-Failure Requirements

    For adult rheumatoid arthritis requests, document that the patient is at least 18 and has not responded to or does not tolerate hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine, unless the applicable criterion specifies another pathway.

    • Also document required failures or contraindications to first-line advanced agents.
    Prior Authorization

    Advanced Therapy Authorization

    Authorize advanced therapy only when the applicable disease-specific criteria are met, including age, diagnosis, conventional-treatment history, advanced-agent sequencing, and specialist involvement.

    • IV agents remain subject to site-of-service review where specified.
    Step Therapy

    Stepwise Prior Authorization

    Apply the policy’s stepwise sequence before approving later-line agents. Record each prior drug, route, duration when available, response, intolerance, and reason for discontinuation.

    • Do not substitute an unlisted product for a required step without documenting a qualifying exception.

    Unsupported block type: documentation

    Prior Authorization

    First-Line TNF-Alpha Antagonist Authorization

    For first-line TNF-alpha antagonists, verify the disease-specific age and diagnosis criteria, required conventional-therapy failure or intolerance, and rheumatologist prescribing or consultation.

    • Examples include adalimumab products, Enbrel, infliximab products, and Simponi Aria depending on the disease pathway.
    Documentation Required

    Prescriber Consultation Requirement

    Document that the medication is prescribed by or in consultation with a rheumatologist whenever the applicable criterion requires it.

    • The consultation requirement applies across multiple first-line and second-line pathways.
    Documentation Required

    Rheumatologist Involvement

    Confirm rheumatologist involvement for disease-specific specialty-drug requests and retain the specialist’s assessment or consultation documentation.

    • A general diagnosis alone does not establish the required specialist involvement.
    Documentation Required

    Rheumatologist Consultation and Treatment History

    For therapies requiring rheumatology consultation, submit the rheumatologist’s assessment together with the treatment history and rationale for the requested agent.

    • Document both specialist involvement and prior treatment response or intolerance.
    Prior Authorization

    Rheumatology-Directed Authorization

    Route authorization through a rheumatology-directed pathway when the criteria require prescribing by or consultation with a rheumatologist.

    • Requests lacking required specialist involvement may not meet medical necessity.
    Prior Authorization

    First-Line Advanced Therapy Authorization

    For first-line advanced therapies, verify the applicable diagnosis, minimum age, conventional-treatment requirements, and specialist involvement before approval.

    • Some first-line agents are still subject to product-specific step requirements.
    Prior Authorization

    TNFα Antagonist Prior Authorization

    For TNF-alpha antagonist requests, apply the disease-specific first-line or second-line sequence and document all required prior failures or exceptions.

    • Route and product matter; IV products may also require site-of-service review.
    Denial Risk

    Unmet Site-of-Service Criteria

    Do not approve hospital-based outpatient administration unless the applicable site-of-service criteria are met.

    • The site is medically necessary for the first 90 days of an initial course or after re-initiation following at least 6 months off therapy, subject to the policy exception for standard dosing.
    • It may also qualify when no infusion center is within 50 miles, no contracted home-infusion agency will travel to the home, the hospital is the only site offering the drug, or the patient has qualifying high-risk clinical conditions.
    Billing Rule

    Incorrect Benefit Processing

    If an IV drug claim is billed to the pharmacy benefit, correct benefit processing; IV drugs described in this policy must be processed through the medical benefit.

    • This is separate from whether the drug and administration site satisfy medical necessity.
    Denial Risk

    Drug-Specific Criteria Not Met

    Deny or pend authorization when drug-specific diagnosis, age, prior-treatment, route, specialist, or site-of-service criteria are not met or are not documented.

    • Apply the criteria associated with the requested product and condition.
    Denial Risk

    Cosmetic Alopecia Use Excluded

    Do not cover tofacitinib when used for alopecia; cosmetic alopecia use is excluded under this policy.

    • The exclusion applies even when the drug may be covered for an otherwise qualifying rheumatoid-arthritis indication.
    Billing Rule

    Custom Formulary Criteria Differ

    The policy criteria do not apply to the identified custom Open formulary plan (Formulary ID 6062; Rx Plan F1). Verify the member’s Plan booklet or ID card and use policy 5.01.647 when applicable.

    • Do not apply this policy’s criteria without confirming formulary applicability.
    Note

    Custom Formulary Criteria Apply

    When the member is not in the custom Open formulary exception, apply this policy’s product-specific medical-necessity and step-therapy criteria.

    • Confirm plan applicability before submitting or adjudicating the request.
    Documentation Required

    Clinical Justification for Hospital Outpatient Administration

    Hospital outpatient administration may be medically necessary for the initial 90-day course or re-initiation after at least 6 months off therapy, when no qualifying lower-cost or safer site is available, or when clinical risk requires hospital-level care.

    • Document the clinical rationale and the applicable site limitation.
    Documentation Required

    Drug Authorization Documentation

    Document the requested drug, strength, route, diagnosis, age, dosing schedule, prior therapies, treatment response or intolerance, prescriber, and rheumatology consultation when applicable.

    • For IV drugs, include the proposed administration site and site-of-service rationale.
    Documentation Required

    Medical Necessity Documentation

    Submit clinical records supporting diagnosis, severity, prior treatment failures or intolerance, contraindications, and any qualifying comorbid exception.

    • Examples of relevant exceptions include heart failure, previously treated lymphoproliferative disorder, serious infection, or demyelinating disorder when listed for the requested drug.
    Documentation Required

    Site-of-Service Documentation

    For IV or injectable drugs subject to SOS review, document the proposed site and why it is the most appropriate, safe, and cost-effective setting.

    • Preferred sites generally include a physician office, infusion center, or home when clinically appropriate.
    • Hospital outpatient is not medically necessary when the policy’s criteria are unmet.
    Documentation Required

    Rheumatoid Arthritis Treatment History

    For rheumatoid arthritis requests, retain the adult patient’s conventional DMARD history, advanced-agent history, response or intolerance, contraindications, and rheumatologist involvement.

    • Verify the requested product’s position in the RA sequence.
    Step Therapy

    Ankylosing Spondylitis Sequencing

    For ankylosing spondylitis, use the specified first-line TNF-alpha, IL-17, or JAK pathway before approving later-line agents.

    • Adults generally must be at least 18 and have prescribing by or consultation with a rheumatologist.
    • Second-line agents require the listed first-line failures or intolerance.
    Step Therapy

    Rheumatoid Arthritis Therapeutic Sequence

    For rheumatoid arthritis, apply the first-line sequence of TNF-alpha inhibitors, IL-6 inhibitors, and JAK inhibitors, followed by the applicable second-line IL-6, IL-1, T-cell costimulation, anti-CD20, or JAK pathway.

    • The exact sequence depends on the requested product and the policy’s listed tier.
    Step Therapy

    Conventional and Advanced Therapy Sequencing

    For disease-specific specialty requests, require conventional therapy failure or intolerance before advanced therapy and require the listed advanced-agent failures before second-line treatment.

    • Document exceptions when the policy allows an alternative pathway.
    Step Therapy

    Conventional DMARD and Advanced-Agent Sequencing

    Require the applicable conventional DMARD step—typically leflunomide, methotrexate, sulfasalazine, or hydroxychloroquine—before approving an advanced agent.

    • The exact conventional agents vary by diagnosis and product.
    Step Therapy

    Conventional DMARD and Targeted-Agent Sequencing

    For targeted agents, verify the required conventional DMARD history and the specified prior biologic or targeted-agent failures before approval.

    • Do not count an agent outside the policy’s listed alternatives unless the applicable criterion permits it.
    Step Therapy

    Advanced Therapy Step Requirement

    Advanced therapy step requirements may include inadequate response or intolerance to two listed agents, or a qualifying clinical exception such as heart failure or a previously treated lymphoproliferative disorder.

    • Prescriber or rheumatologist consultation remains required where specified.
    Step Therapy

    Conventional Antirheumatic Step

    Verify the required first-line conventional antirheumatic step before approving a specialty agent.

    • For rheumatoid arthritis, listed agents include hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine.
    Step Therapy

    Conventional Therapy and Advanced-Agent Sequencing

    Require conventional therapy followed by the applicable advanced-agent sequence, including first-line TNF blockers and later-line biologic or targeted therapies.

    • Record inadequate response, intolerance, or a policy-listed exception for every required step.
    Step Therapy

    Prior Therapy and Exception Pathway

    When a required prior therapy cannot be used, document the clinical exception and the alternative sequence supported by the policy.

    • Qualifying exceptions may include heart failure, prior lymphoproliferative disorder, serious infection, or demyelinating disorder when specifically listed.
    Denial Risk

    Authorization Denial Risks

    Do not approve a request when required site-of-service criteria are absent, the requested product is not medically necessary for the diagnosis, required prior therapy is undocumented, or the specialist requirement is unmet.

    • The member’s benefit and formulary must also be verified.

    Background

    Arthropathy refers to arthritis and may cause joint inflammation, pain, swelling, stiffness, and loss of motion. Inflammatory arthropathies involve joint inflammation and altered immune regulation; autoimmune disease occurs when immune cells attack joints or other organs. This policy addresses biologic and other targeted therapies for ankylosing spondylitis, juvenile idiopathic arthritis, nonradiographic axial spondyloarthritis, polymyalgia rheumatica, and rheumatoid arthritis.

    Definitions

    Site of service
    DefinitionThe location where a drug is administered
    ExamplesHospital-based outpatient setting, infusion center, physician's office, or home
    Policy useThe location is reviewed for medical necessity when site-of-service criteria apply
    Biologics
    DefinitionSpecial medications used to treat inflammatory conditions
    Included agentsBiologic agents
    Policy contextThe policy discusses when biologics are medically necessary for inflammatory conditions
    Initial or re-initiation therapy
    Initial therapyThe initial course of infusion or injection of a pharmacologic or biologic agent
    Re-initiationRestarting an agent after 6 months or longer following discontinuation
    Not includedStandard dosing between infusions or injections when the interval is 6 months or longer
    Enthesitis-related arthritis
    DefinitionA category of juvenile idiopathic arthritis
    Clinical featuresIncludes children with arthritis and enthesitis
    EnthesitisInflammation where tendons, ligaments, or joint capsules attach to bone
    Aggressive disease
    Policy termAggressive disease
    Use in criteriaRequired for specified polyarticular juvenile idiopathic arthritis therapies
    Definition locationDetailed definition is in the policy's Related Information section
    TNF-alpha antagonists
    Drug categoryFirst-line drug category
    TargetTumor necrosis factor alpha
    Policy controlsSubject to authorization and site-of-service review provisions
    Inadequate response or intolerance
    Inadequate responseThe member does not achieve sufficient clinical benefit
    IntoleranceThe medication cannot be continued because of adverse effects
    DocumentationThe response or intolerance must be documented for the applicable therapy pathway
    Inadequate response or intolerance to 2 agents
    Required number2 agents
    Response standardInadequate response or intolerance
    Agent groupListed targeted agents
    TNF-alpha antagonists
    Drug categoryFirst-line treatment category
    Full termTumor necrosis factor alpha antagonists
    Review contextIncluded among drugs subject to site-of-service review
    Inadequate response or intolerance
    Inadequate responseThe patient has not achieved an adequate clinical response
    IntoleranceThe patient cannot continue the medication because of adverse effects or other documented tolerability problems
    Pathway useUsed to establish eligibility for the applicable advanced therapy
    TNF-alpha antagonists - first line
    Treatment positionFirst-line advanced pharmacotherapy
    Prior therapyAfter inadequate response or intolerance to specified conventional therapies
    Additional requirementsSubject to advanced-agent or clinical-exception criteria
    TNFα antagonist
    Full termTumor necrosis factor alpha antagonist
    Treatment positionFirst-line pharmacotherapy group
    Policy contextPart of the targeted treatment pathway for arthropathies

    Initial Therapy Criteria

    Ankylosing spondylitis first-line therapy

    Initial therapy may include the listed first-line options.

    Initial therapy: The individual meets the applicable age requirement and the medication is prescribed by or in consultation with a rheumatologist.Generally age 18 years or older

    Polyarticular juvenile idiopathic arthritis first-line therapy

    Initial therapy includes the listed first-line TNF-alpha, JAK, and IL-6 agents.

    Initial polyarticular JIA therapy: The individual is at least 2 years old; for specified TNF-alpha agents, has aggressive disease and inadequate response or intolerance to, or concurrent initiation with, leflunomide, methotrexate, or sulfasalazine; and the medication is prescribed by or in consultation with a rheumatologist.Age 2 years or older

    Cosentyx initial therapy

    Cosentyx is the listed first-line agent.

    Initial Cosentyx therapy: The individual has enthesitis-related arthritis, is at least 4 years old, and Cosentyx is prescribed by or in consultation with a rheumatologist.Age 4 years or older

    Rheumatoid arthritis initial therapy

    Initial rheumatoid arthritis therapy requires the applicable prior-treatment pathway.

    Rheumatoid arthritis initial therapy: The individual is at least 18 years old, has moderate-to-severe rheumatoid arthritis, meets the requested agent's prior-treatment failure or intolerance requirement, and treatment is prescribed by or in consultation with a rheumatologist.Age 18 years or older

    Polyarticular JIA initial therapy

    Second-line polyarticular JIA agents require conventional-therapy failure and the applicable targeted-agent pathway.

    Initial authorization: The individual is at least 2 years old, has aggressive disease, has inadequate response or intolerance to leflunomide, methotrexate, or sulfasalazine, meets the product-specific targeted-agent requirement, and treatment is prescribed by or in consultation with a rheumatologist.Age 2 years or older

    Systemic JIA initial therapy

    The listed IL-6 inhibitors are first-line agents for systemic JIA.

    Systemic JIA initial therapy: The individual is at least 2 years old, has inadequate response or intolerance to the required prior therapy, and treatment is prescribed by or in consultation with a rheumatologist.Age 2 years or older

    JAK inhibitors

    Covered for moderate-to-severe rheumatoid arthritis when all criteria are met.

    JAK inhibitor initial therapy: The individual is at least 18 years old, has inadequate response or intolerance to one or more TNF blockers, and treatment is prescribed by or in consultation with a rheumatologist.Age 18 years or older; at least one TNF blocker failed or not tolerated

    TNF antagonists

    Covered after conventional therapy and the applicable advanced-agent step.

    TNF antagonist therapy: The individual is at least 18 years old, has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine, and, where required, has inadequate response or intolerance to two listed advanced agents.Age 18 years or older

    Advanced biologic pathways

    Product-specific requirements apply.

    Product-specific pathways: Infliximab requires inadequate response or intolerance to Avsola, Inflectra, and Renflexis when applicable; Kevzara requires two specified advanced-agent failures or the stated clinical pathway; Kineret requires two specified advanced-agent failures.

    Orencia

    Covered under the adult, conventional-therapy, and advanced-therapy requirements.

    Orencia initial therapy: The individual is at least 18 years old, has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine, meets an advanced-therapy pathway, and treatment is prescribed by or in consultation with a rheumatologist.Age 18 years or older

    Initial TNF-alpha antagonist therapy

    Initial coverage requires adult age, conventional-therapy failure, and one qualifying pathway.

    Initial therapy requirements

    • Qualifying pathway: Inadequate response or intolerance to two specified agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    TNF-alpha antagonist first-line therapy

    First-line advanced therapy requires conventional-therapy failure and an applicable advanced-agent pathway.

    Initial therapy

    • Advanced-agent pathway: Inadequate response or intolerance to two listed agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    TNF-alpha antagonist first-line therapy

    Initial targeted therapy requires the conventional-agent prerequisite and one additional pathway.

    Conventional therapy

    • Additional pathway: Inadequate response or intolerance to two listed targeted agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Initial therapy authorization

    Initial coverage requires the applicable step-therapy criteria.

    Initial authorization

    • Additional qualification: Inadequate response or intolerance to two listed advanced agents, or a qualifying pathway involving heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Initial targeted therapy

    Initial therapy is subject to the conventional-agent prerequisite and one alternative pathway.

    Initial therapy

    • Alternative pathways: Inadequate response or intolerance to two listed targeted agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Initial advanced therapy

    Initial advanced therapy requires the applicable clinical and step-therapy pathway.

    Initial therapy: The member has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine and meets an advanced-agent failure or clinical-exception pathway.Two agents or one qualifying condition

    Initial targeted therapy

    Initial targeted therapy requires conventional-therapy failure and one qualifying pathway.

    Initial therapy

    • Subsequent qualification: Inadequate response or intolerance to two listed targeted agents, or the specified clinical-exception pathway; treatment is prescribed by or in consultation with a rheumatologist.Two targeted agents or one qualifying condition

    Initial TNF-alpha antagonist authorization

    Initial therapy is covered when all listed requirements are met.

    Initial authorization: The patient has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; meets a targeted-agent failure or qualifying-condition pathway; and treatment is prescribed by or in consultation with a rheumatologist.Two targeted agents or one qualifying condition

    First-line specialty-drug authorization

    Initial therapy requires conventional-therapy failure, rheumatology involvement, and one qualifying pathway.

    Baseline

    • Qualifying pathway: Inadequate response or intolerance to two listed specialty agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Initial first-line advanced therapy

    Initial first-line advanced therapy requires the base requirements and one pathway.

    Initial therapy

    • Advanced-therapy pathway: Inadequate response or intolerance to two listed advanced agents, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Initial TNF-alpha antagonist therapy

    Initial first-line TNF-alpha antagonist therapy requires all listed criteria.

    Initial therapy: The patient has inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine; meets a two-agent or clinical-exception pathway; and treatment is prescribed by or in consultation with a rheumatologist.Two agents or one qualifying condition

    TNFα antagonist initial therapy

    Initial therapy is subject to the applicable prior-treatment and clinical-history criteria.

    Initial authorization

    • Qualifying pathway: Inadequate response or intolerance to two listed agents or agent groups, or heart failure, a previously treated lymphoproliferative disorder, a previous serious infection, or a demyelinating disorder.Two agents or one qualifying condition

    Step Therapy

    StepTherapy or agentsRequirement
    First lineInflectra, Renflexis, Simponi Aria, specified adalimumab products, Taltz, or RinvoqFor applicable second-line requests, demonstrate inadequate response or intolerance to one or two listed first-line agents, depending on the requested drug.
    StepTherapy or agentsRequirement
    First lineTNF-alpha inhibitors, JAK inhibitors, and IL-6 inhibitorsUse the listed first-line tier when applicable age, aggressive-disease, conventional-therapy, and rheumatologist requirements are met.
    Second lineAdditional TNF inhibitors, Orencia, Kevzara, and other specified agentsGenerally requires inadequate response or intolerance to required conventional DMARDs and, where specified, one or two listed biologic or targeted therapies.
    StepTherapy categoryAgents or examples
    1TNF-alpha inhibitorsInfliximab, Remicade, Cimzia, Immgolis, Simponi, and listed adalimumab products
    2IL-6 inhibitorKevzara
    3IL-1 inhibitorKineret
    4T-cell costimulation modulatorOrencia IV/SC
    5Janus kinase inhibitorOlumiant oral
    StepTherapy categorySubsequent option
    2IL-6 inhibitorKevzara, after the first-line TNF-alpha inhibitor pathway.
    StepTherapy categorySubsequent option
    3IL-1 inhibitorKineret, after the first-line TNF-alpha inhibitor pathway.
    StepTherapy categorySubsequent option
    4T-cell costimulation modulatorOrencia IV/SC, after the first-line TNF-alpha inhibitor pathway.
    StepTherapy categorySubsequent option
    5Janus kinase inhibitorOlumiant oral, after the first-line TNF-alpha inhibitor pathway.
    StepTherapy or agentsRequirement
    Second lineKevzara, Orencia, Cimzia, and selected TNF-alpha antagonistsDocument inadequate response or intolerance to leflunomide, methotrexate, or sulfasalazine and, where specified, two listed targeted agents or all specified first-line adalimumab products. Certain serious comorbidities may provide an alternative pathway.
    StepRequested therapyPrerequisite
    2Rinvoq, tofacitinib, tofacitinib extended-release, Xeljanz, or Xeljanz XRFor moderate-to-severe rheumatoid arthritis, demonstrate inadequate response or intolerance to one or more TNF blockers.
    StepBefore treatmentRequirement
    1TNF blockerAn inadequate response or intolerance to at least one TNF blocker is required before the listed rheumatoid arthritis JAK inhibitors.
    StepTherapy sequenceRequirement
    1Conventional DMARDsUse hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine as applicable before advanced therapy.
    2Advanced biologic or targeted agentsFor selected second-line therapies, document failure or intolerance of two specified advanced agents after the conventional-therapy step.
    StepRequested therapyPrerequisite
    1Unbranded Janssen infliximab or RemicadeFor individuals not previously treated with the requested therapy, demonstrate inadequate response or intolerance to Avsola, Inflectra, and Renflexis.
    StepTherapy pathwayRequirement
    1Conventional therapyDemonstrate inadequate response or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    2Advanced-agent pathwayThen demonstrate inadequate response or intolerance to two specified agents, unless a qualifying clinical exception applies.
    StepTherapy pathwayRequirement
    1Conventional DMARDsTry and fail or not tolerate hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    2Advanced therapyThe applicable pathway may additionally require failure or intolerance of two listed advanced agents.
    StepTherapy pathwayRequirement
    1Conventional therapyDemonstrate nonresponse or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    2Targeted agentsThe pathway may require inadequate response or intolerance to two listed targeted agents or may use the specified serious-comorbidity pathway.
    StepTherapy pathwayRequirement
    1Conventional therapyTrial and failure or intolerance of hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    2Advanced therapyThen demonstrate inadequate response or intolerance to two listed advanced agents, unless an alternate qualifying-condition pathway applies.
    StepTherapy pathwayRequirement
    1Conventional antirheumatic therapyTry hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine before targeted therapy.
    2Targeted therapyGenerally demonstrate inadequate response or intolerance to two listed targeted agents unless a clinical exception applies.
    StepTherapy pathwayRequirement
    1Conventional therapyTry and fail or not tolerate hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    2Advanced therapyAdditionally demonstrate failure or intolerance to two listed advanced agents, unless the clinical-exception pathway applies.
    StepTherapy pathwayRequirement
    1Conventional therapyDemonstrate nonresponse or intolerance to hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    2Targeted agentsGenerally demonstrate inadequate response or intolerance to two listed targeted agents, unless the specified clinical-exception pathway applies.
    StepTherapy pathwayRequirement
    1Conventional DMARDsFail or not tolerate hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine.
    2Targeted agentsAdditionally fail or not tolerate at least two specified targeted agents unless the qualifying clinical-condition pathway applies.
    StepTherapy pathwayRequirement
    1Conventional therapyDocument failure or intolerance of hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine before the specialty drug.
    2Specialty agentsUnder the standard pathway, document failure or intolerance of two listed specialty agents; an alternate clinical pathway may apply.
    StepTherapy pathwayRequirement
    1Conventional therapyFail or not tolerate hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine.
    2Advanced therapyEstablish failure or intolerance to two listed advanced agents, unless the clinical-risk-factor pathway applies.
    StepTherapy pathwayRequirement
    1Conventional therapyFail or not tolerate hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine before first-line TNF-alpha antagonist therapy.
    2Advanced-agent pathwayUnder the standard pathway, demonstrate inadequate response or intolerance to two listed agents; a clinical-exception pathway may apply.
    StepTherapy pathwayRequirement
    1Conventional therapyFailure or intolerance of hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine is required.
    2Advanced agentsUnder the standard pathway, failure or intolerance of two listed advanced agents is required before authorization.
    StepTherapy pathwayRequirement
    1Conventional therapyDocument failure or intolerance of the applicable conventional therapies, including hydroxychloroquine, leflunomide, methotrexate, or sulfasalazine as specified.
    2Targeted-agent pathwayDemonstrate failure or intolerance to two listed targeted agents or agent groups, unless the applicable qualifying clinical-history pathway is met.

    Site of Care

    Billing Rule

    Use an appropriate physician office site

    Use a physician's office when it is the most appropriate, safe, and cost-effective site for IV infusion or injection therapy and the applicable criteria are met.

    Billing Rule

    Use an appropriate infusion center

    Use an infusion center as a preferred medically necessary site when it is the most appropriate, safe, and cost-effective setting and the applicable criteria are met.

    Billing Rule

    Support hospital outpatient administration

    Hospital-based outpatient administration is medically necessary for the first 90 days of initial or reinitiated therapy, when access limitations apply, when the hospital is the only site offering the drug, or when a qualifying clinical risk requires that setting.

    Billing Rule

    Confirm home-infusion availability

    Use home infusion when a contracted agency is available and will travel to the individual's home; absence of such an agency may support hospital-based outpatient administration.

    Prior Authorization

    Review listed IV products

    Submit Orencia IV, Actemra IV, Avtozma IV, Tofidence IV, Tyenne IV, Avsola IV, Inflectra IV, Renflexis IV, and Simponi Aria IV for site-of-service review.

    Prior Authorization

    Review infliximab site of service

    Submit unbranded Janssen infliximab and Remicade for site-of-service administration review.

    Prior Authorization

    Review Orencia IV site of service

    Submit Orencia IV for site-of-service administration review.

    Documentation Required

    Submit site-of-service information

    Apply site-of-service review to drugs identified in the policy and document the requested administration setting and supporting information.

    Prior Authorization

    Verify site-of-service requirements

    For the identified drugs, verify the applicable site-of-service requirements before administration and submit supporting information when requested.

    Prior Authorization

    Review listed targeted agents

    Treat the listed TNF-alpha antagonist and targeted agents as subject to site-of-service review under the policy.

    Prior Authorization

    Submit drugs for site review

    Submit listed drugs identified as subject to site-of-service review under this policy section for the applicable review.

    Note

    Confirm site-of-service requirements

    Confirm the applicable site-of-service review requirements for the listed drugs before administration; the cited excerpt does not provide an additional operational setting rule.

    Biosimilar and Reference Products

    Billing Rule

    Verify adalimumab product status

    For the specified adalimumab products, verify the product and apply the applicable first-line or second-line criteria; products with NDCs starting with 00597 are identified in the policy.

    Billing Rule

    Use the listed infliximab products

    Avsola, Inflectra, and Renflexis are listed as first-line infliximab products and are subject to site-of-service review when administered intravenously.

    Step Therapy

    Sequence infliximab biosimilars

    For individuals not previously treated with the requested therapy, establish inadequate response or intolerance to Avsola, Inflectra, and Renflexis before requesting unbranded Janssen infliximab or Remicade.

    Documentation Required

    Document subcutaneous tocilizumab history

    Avtozma and Tyenne subcutaneous products appear in the targeted-agent step-therapy options alongside Actemra; document their use when relied upon in the pathway.

    Billing Rule

    Verify specified adalimumab identifiers

    The specified adalimumab products—adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm—are identified by NDCs starting with 00597 and appear in the targeted-agent options.

    Step Therapy

    Include Avtozma in prior-treatment review

    Avtozma is listed alongside Actemra as an agent that may be evaluated in the prior-treatment pathway.

    Step Therapy

    Include Tyenne in prior-treatment review

    Tyenne is listed alongside Actemra as an agent that may be evaluated in the prior-treatment pathway.

    Policy Summary
    PayerPremera Bluecross
    PolicyPharmacotherapy of Arthropathies
    Policy CodePolicy 5.01.550
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionDocument the diagnosis, age, prior treatment response or intolerance, and rheumatologist prescribing or consultation for authorization.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Operational ParametersProvider Actions and Authorization RequirementsBackgroundDefinitionsInitial Therapy CriteriaStep TherapySite of CareBiosimilar and Reference Products